International Journal of Cancer最新文献

{"title":"The TESTBREAST journey: Revisiting the importance of early detection by frequent screening of women at high risk of breast cancer.","authors":"Layla Andour, Sophie C Hagenaars, Kiki Vangangelt, Janneke Aalberts, Valerie Rebattu, Dorien M A Berends van der Meer, Elma Meershoek-Klein Kranenbarg, Katja N Gaarenstroom, Christi J van Asperen, Rob A E M Tollenaar, Wilma E Mesker","doi":"10.1002/ijc.35444","DOIUrl":"https://doi.org/10.1002/ijc.35444","url":null,"abstract":"<p><p>Women with an inherited pathogenic variant (PV) in a breast cancer (BC) susceptibility gene, or familial predisposition (FP) have an increased risk to develop BC. There is a need for improvement of screening methods due to interval cancers and radiation exposure. The aim of the TESTBREAST study is to develop a blood test suitable for early diagnosis. Here, the clinical composition of participants is provided. From 2010 to 2022, 1108 women were included in the TESTBREAST study, with currently 750 participants suitable for serum analysis. The median follow-up was 7 years [1-14]. Of the 1108 participants, 70% (n = 728) had a PV. BC was diagnosed in 16.5% (n = 124), mainly stage I-II (68.5%), and mostly BRCA1 (n = 47, 47%) and BRCA2 (n = 29, 29%) carriers. Invasive cancer was diagnosed in 100 cases: 76% (n = 76) had a PV with a median age of 49 [26-68] at diagnosis, whereas 24% (n = 24) had a FP, with a median age of 51 years [25-65]. The general population (the Netherlands) is aged 61 years on average at diagnosis. Triple negative breast cancer (TNBC) occurred in 51% (n = 39) of the TESTBREAST women with a PV, whereas this was 11% in the general population. Within the TESTBREAST cohort, BRCA carriers were younger at diagnosis and often had the aggressive TNBC subtype. Improvement of current screening methods for early detection is especially important for this group of high-risk women to reduce interval cancers, exposure to radiation, and to improve survival.</p>","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":5.7,"publicationDate":"2025-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143954226","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Deregulated enhancer-promoter communication in cancer through altered nuclear architecture.","authors":"Isabelle Seufert, Claire Vargas, Sina Jasmin Wille, Karsten Rippe","doi":"10.1002/ijc.35424","DOIUrl":"https://doi.org/10.1002/ijc.35424","url":null,"abstract":"<p><p>Enhancers are critical regulators of gene expression. Structural variations in cancer genomes can lead to enhancer hijacking, where oncogenes are activated by mistargeted enhancer activity. Novel enhancer-promoter interactions may also arise through chromosomal rearrangements that create extrachromosomal DNA elements. Additionally, fusion proteins and other mutation-induced alterations in protein properties can lead to the aberrant assembly of proteins into large complexes on the size scale of 0.1-1 μm termed onco-condensates. Transcription factors and co-activators accumulate with cis-regulatory elements in these structures, driving oncogenic programs. Here, we review current evidence of how altered genome architecture and macromolecular assembly result in deregulated enhancer-promoter communication. We discuss emerging strategies to exploit these mechanisms for clinical applications.</p>","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":5.7,"publicationDate":"2025-04-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143952170","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Human sporadic breast carcinoma histotypes driven by the Human Betaretrovirus homologous to Mouse Mammary Tumor Virus","authors":"Prospero Civita,&nbsp;Chiara Maria Mazzanti,&nbsp;Francesca Lessi,&nbsp;Caterina Marchiò,&nbsp;Cristian Scatena,&nbsp;Michele Menicagli,&nbsp;Matteo Ghilli,&nbsp;Manuela Roncella,&nbsp;Antonio Giuseppe Naccarato,&nbsp;Anna Sapino,&nbsp;Jacob Hochman,&nbsp;Mauro Pistello,&nbsp;Generoso Bevilacqua","doi":"10.1002/ijc.35438","DOIUrl":"https://doi.org/10.1002/ijc.35438","url":null,"abstract":"<p>The viral hypothesis for human sporadic breast carcinoma is based on the murine model of Mouse Mammary Tumor Virus (MMTV)-induced mammary tumors. Known risk factors like estrogens, obesity, and alcohol do not play a direct causal role. The Human Betaretrovirus (HBRV), also called Human Mammary Tumor Virus (HMTV), is the human homolog of MMTV, implicated in sporadic breast carcinoma (80% of ductal carcinoma in situ and 40% of invasive tumors). In contrast, hereditary breast carcinomas lack viral sequences. Murine mammary tumor histotypes are determined by specific viral strains activating definite molecular pathways via insertional mutagenesis. Similarly, the diverse histotypes observed in human invasive breast carcinoma may be influenced by a viral etiology. A study of 253 invasive breast carcinoma cases, representing 15 histotypes, detected HBRV/MMTV-<i>ENV</i> sequences in 20%, consistent with international literature. All histotypes tested positive except those linked to hereditary syndromes, such as medullary, apocrine, and metaplastic carcinoma. This distinction reinforces the reported lack of association between HBRV/HMTV and hereditary breast cancer, while supporting a viral etiology for sporadic carcinoma. Relevant characteristics of sporadic histotypes align with the “hit and run” hypothesis of viral carcinogenesis. Histotype differences may result from molecular pathways activated by Int genes, though mechanism beyond insertional mutagenesis and the possibility of specific HBRV strains cannot be ruled out. The potential for detected viral sequences to originate in human tumors from endogenous MMTV or contamination with murine material is critically examined.</p>","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":"157 2","pages":"371-383"},"PeriodicalIF":5.7,"publicationDate":"2025-04-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/ijc.35438","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143949888","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A strategy for multimodal integration of transcriptomics, proteomics, and radiomics data for the prediction of recurrence in patients with IDH-mutant gliomas.","authors":"Tiffanie Chouleur, Christèle Etchegaray, Laura Villain, Antoine Lesur, Thomas Ferté, Marco Rossi, Laetitia Andrique, Costanza Simoncini, Anne-Sophie Giacobbi, Matteo Gambaretti, Egesta Lopci, Bethania Fernades, Gunnar Dittmar, Rolf Bjerkvig, Boris Hejblum, Rodolphe Thiébaut, Olivier Saut, Lorenzo Bello, Andreas Bikfalvi","doi":"10.1002/ijc.35441","DOIUrl":"https://doi.org/10.1002/ijc.35441","url":null,"abstract":"<p><p>Isocitrate dehydrogenase-mutant gliomas are lethal brain cancers that impair quality of life in young adults. Although less aggressive than glioblastomas, IDH-mutant gliomas invariably progress to incurable disease with unpredictable recurrence. A better classification of patient risk of recurrence is needed. Here, we describe a multimodal analytical pipeline integrating imaging, transcriptomic, and proteomic profiles using machine learning to improve patient stratification with novel signatures of patient risk of recurrence based on gene expression, protein level, and imaging. Additionally, we describe the biological characteristics of IDH-mutant glioma subtypes categorized by positron emission tomography (PET) and histology, and we reinforce the integration of positron emission tomography (PET) metrics in the classification of IDH-mutant gliomas. We identify a gene signature (KRT19, RUNX3, and SCRT2) and a protein signature (ATXN10, EIF4H, ITGAV, and NCAM1) associated with an increased risk of early recurrence. Furthermore, we integrated these markers with imaging-derived features, obtaining a better stratification of IDH-mutant glioma patients in comparison to histomolecular classification alone.</p>","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":5.7,"publicationDate":"2025-04-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143958598","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Invitation for FOBt screening and colorectal cancer mortality: A prospective analysis in the Million Women Study cohort.","authors":"Roger G Blanks, Rupert J Alison, Gillian K Reeves","doi":"10.1002/ijc.35437","DOIUrl":"https://doi.org/10.1002/ijc.35437","url":null,"abstract":"<p><p>Using linked data from the Million Women Study (MWS) cohort and the NHS Bowel Cancer Screening Programme (NHS BCSP) offering biennial guaiac faecal occult blood test (gFOBt) screening from 2006, we examined factors associated with screening acceptance, and differences in colorectal cancer (CRC) mortality by screening invitation status. Characteristics of attenders and non-attenders were compared among 752,007 MWS participants born 1940-1950, who were all invited for at least one round of routine screening. Women declining screening had higher deprivation and smoking levels, and a 2-fold risk of all-cause and CRC mortality compared with women who accepted. Of 246,160 women born in 1935-1939, 111,956 were assigned to the \"no intention to invite\" group, and 134,204 to the \"intention to invite\" group based on year of birth and postcode sector, with an average of 0.01 and 2.40 screening invitations in each group, respectively. During a mean follow up of 11.9 years, there were 858 and 791 CRC deaths in the \"intention to invite\" and \"no intention to invite\" groups, respectively. In the period 4 or more years after study entry there was no significant reduction in risk of death from CRC associated with invitation for screening (RR = 0.94, 95%CI 0.83-1.06), but evidence of differences in associations by anatomical sub-site, with a reduction in deaths from distal colon cancer (0.64, 0.47-0.88), but not proximal (1.02, 0.83-1.25) or rectal cancer (0.97, 0.79-1.20) (p-value for heterogeneity by subsite = 0.05). Investigation of the effectiveness of current bowel screening methods using faecal immunochemical testing (FIT) by sex and cancer sub-site is warranted.</p>","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":5.7,"publicationDate":"2025-04-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143955660","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Technical, legal and ethical framework of cancer audit in cervical screening – Summary of best practices for organised programmes delineated through an expert group consultation","authors":"Arunah Chandran,&nbsp;Anne Mackie,&nbsp;Peter Sasieni,&nbsp;Marc Arbyn,&nbsp;Andre L. Carvalho,&nbsp;Clement Chauvet,&nbsp;Walter Prendiville,&nbsp;Elisabete Weiderpass,&nbsp;Partha Basu,&nbsp;CervScreen Technical Working Group","doi":"10.1002/ijc.35403","DOIUrl":"https://doi.org/10.1002/ijc.35403","url":null,"abstract":"<p>Efficient and well-organised cervical screening programmes have significantly reduced both the incidence and mortality rates of cervical cancer in the population. For optimal performance, such programmes need to incorporate essential quality assurance measures. The International Agency for Research on Cancer (IARC/WHO) organised an expert consultation to delineate best practices in auditing cancers in a cervical screening programme, the legal and ethical frameworks governing such audits, and communicating audit outcomes. As a best practice, every programme should have a well-documented policy and process framework for cancer audits. The TWGs agreed that the primary goal of programmatic cancer audits is to assess the programme's effectiveness in lowering cervical cancer incidence and minimising screening-related risks. Using audit results, informed decisions can be made to enhance service delivery, including professional training, adopting improved screening tests, strengthening fail-safe mechanisms, reducing delays, and minimising inequalities. Legal complexities in cervical screening stem from its inherent limitations and risks, and differentiating cases of negligence from inevitable and non-negligent errors where an abnormality is not detected but actually exists is crucial. TWGs suggested that determining whether a screening error was serious enough to be categorised as negligent and/or to entitle the patient to compensation should reflect the inherent limitations of cervical screening. Data obtained while performing screening tests and subsequent diagnostic tests or treatments are sensitive and need to be safeguarded. The best practice document drafted through expert consultation will help cervical screening programmes standardise practices related to cancer audits and address associated legal and ethical issues.</p>","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":"157 1","pages":"32-40"},"PeriodicalIF":5.7,"publicationDate":"2025-04-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/ijc.35403","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143925831","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Time to pathologic diagnosis of suspicious breast lesions: An institution-based study in five Ethiopian hospitals.","authors":"Friedemann Rabe, Sefonias Getachew, Clara Yolanda Stroetmann, Nikolaus Christian Simon Mezger, Tewodros Yalew Gebremariam, Bereket Berhane, Alex Mremi, Blandina Theophil Mmbaga, Pauline Boucheron, Valerie McCormack, Pablo Santos, Adamu Addissie, Eva Johanna Kantelhardt","doi":"10.1002/ijc.35436","DOIUrl":"https://doi.org/10.1002/ijc.35436","url":null,"abstract":"<p><p>Most breast cancer (BC) patients in sub-Saharan Africa are diagnosed at advanced stages. The World Health Organization's Global Breast Cancer Initiative Pillar II has a benchmark to diagnose BC within 2 months of the first contact with a health care provider (HCP). In this study, we interviewed 345 women who received a diagnostic workup of a suspicious breast lesion (eventually diagnosed as benign or malignant) at five Ethiopian hospitals in 2022. We assessed the length of the diagnostic journey encompassing the pre-contact interval between the first experience of symptoms and the first HCP visit, and the post-contact interval between HCP visit and diagnostic pathology procedures. We used negative binomial regression models to identify factors influencing these time intervals. The median pre-contact interval was 2.8 months (interquartile range [IQR] 0.5-9.8). The median post-contact interval was 1.7 months (IQR 0.6-3.9). Regarding the post-contact interval, 55% of patients received their pathologic diagnosis within the recommended 2 months after the first HCP visit and met the Global Breast Cancer Initiative's benchmark. Increased travel times, limited social support, and consulting multiple HCPs before seeking pathology evaluation prolonged post-contact intervals. Older patients (>45 years) and those referred for pathology evaluation during the initial HCP visit experienced shorter post-contact intervals. Of all 345 women, 39% were diagnosed with BC. The relatively low proportion of women diagnosed within the recommended time frame makes it evident that increased awareness for BC, easily accessible diagnostic services, and specific training for HCPs are essential for the timely diagnosis of BC in Ethiopia.</p>","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":5.7,"publicationDate":"2025-04-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143957878","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Body mass index as a predictive factor for efficacy of adjuvant taxane-based chemotherapy in early-stage breast cancer patients: A pooled analysis from adjuvant GEICAM Spanish Breast Cancer Group and TRIO Translational Research in Oncology Group studies.","authors":"José A García-Saenz, Gonzalo Spera, Marina Pollán, Begoña Bermejo, Manuel Ruiz-Borrego, Arlene Chan, Miguel Martín, Ángel Guerrero-Zotano, Lourdes Calvo, Álvaro Rodríguez-Lescure, María Marín, Linnea Chap, John Crown, Tadeusz Pienkowski, Valerie Bee, Maribel Casas, Óscar Polonio, Susana Bezares, Dennis Slamon","doi":"10.1002/ijc.35432","DOIUrl":"https://doi.org/10.1002/ijc.35432","url":null,"abstract":"<p><p>Adjuvant anthracyclines and taxanes reduce recurrence and death in early-stage breast cancer (EBC) patients, but toxicity is a concern. Studies show conflicting results on the correlation between body mass index (BMI) and outcomes. Limited data exist on the efficacy of adjuvant taxanes among BMI categories and the impact of different taxane-based chemotherapies (paclitaxel vs. docetaxel) on disease recurrence. Here, we present a pooled analysis of 13,486 EBC patients treated with adjuvant anthracyclines ± taxanes from seven GEICAM and TRIO trials (1996-2008) conducted. Patients were classified into four BMI categories: normal (<25.0), overweight (25.0-29.9), obese (30.0-34.9), and severely obese (≥35.0). BMI was evaluated as a predictive factor for the efficacy and toxicity of taxane-based chemotherapy. Our results show the following findings: patients' distribution by BMI was 44% normal, 33% overweight, 16% obese, and 8% severely obese. Seventy-nine percent received taxane-based chemotherapy. Ten-year invasive disease-free survival (iDFS) was 71%, 70%, 68%, and 64% for normal, overweight, obese, and severely obese patients, respectively. Obese and severely obese patients had significantly worse outcomes (HR 1.15 and 1.29, respectively). Invasive disease-free survival with docetaxel vs. non-docetaxel was significant in the normal BMI group, while iDFS with paclitaxel was significant in the obese group. Relevant toxicity was observed in 5%, 5.5%, 5.9%, and 9.3% of normal, overweight, obese, and severely obese patients who received docetaxel. In conclusion, heavier EBC patients had a worse prognosis with adjuvant taxane-based chemotherapy. Normal BMI patients benefited more from docetaxel, while obese patients benefited more from paclitaxel.</p>","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":5.7,"publicationDate":"2025-04-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143952044","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Role of fragile sites FATS and FMR1 in tumor progression and their potential clinical significance","authors":"Chuangdong Ruan,&nbsp;Yichun Xie,&nbsp;Huabin Ye,&nbsp;Yuqin Zhang,&nbsp;Rongxin Zhang,&nbsp;Yan Li","doi":"10.1002/ijc.35417","DOIUrl":"10.1002/ijc.35417","url":null,"abstract":"<p>The fragile sites are defined as specific segments of genes that are particularly susceptible to breakage under conditions of accelerated replication stress or certain external influences. It has been demonstrated that fragile sites can influence the progression of various tumors. However, the majority of existing studies have focused on the functions of well-characterized common fragile sites, such as <i>FHIT</i>, <i>WWOX</i>, and <i>PARK2</i>, in different oncogenic processes, with insufficient attention directed towards other fragile sites. This article presents an analysis of recent investigations into the fragile sites, fragile site-associated tumor suppressor (<i>FATS</i>) and fragile X mental retardation 1 (<i>FMR1</i>), across various tumor types. The article discusses the mechanisms and signaling pathways regulated by these sites in a range of cancers, as well as their clinical implications for tumor treatment. The review highlights the significance of the fragile sites <i>FATS</i> and <i>FMR1</i> in various cancers and their clinical relevance.</p>","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":"157 2","pages":"207-217"},"PeriodicalIF":5.7,"publicationDate":"2025-04-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143810140","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Survival outcomes in small intestine tumors: The role of duodenum, jejunum, and ileum.","authors":"Hongwei Wu, Xiaobao Yang, Wei Guo","doi":"10.1002/ijc.35379","DOIUrl":"https://doi.org/10.1002/ijc.35379","url":null,"abstract":"<p><p>Small intestine tumors are rare, with variable prognostic factors. The impact of tumor location on survival outcomes remains controversial. This study explores the influence of tumor location (duodenum, jejunum, ileum) on survival. We analyzed data from the SEER database for small intestine cancer patients diagnosed between 2010 and 2017. Survival outcomes by tumor location were assessed using the Kaplan-Meier method and competing risk models, stratified by adenocarcinoma (ADC), neuroendocrine tumor (NET), and gastrointestinal stromal tumor (GIST). Propensity score matching (PSM) was employed to adjust for confounders. The cohort included 6047 patients: 2611 with duodenum, 2584 with ileum, and 852 with jejunum tumors. ADC was predominant in the duodenum (51.4%), while NET was most common in the ileum (84.21%). Overall, the ileum tumors had the best prognosis, and duodenum tumors had the worst (p < .001). In ADC, duodenum tumors had the poorest overall (OS) and disease-specific survival (DSS) (p < .001) with no significant impact of location in GIST (p > .05). The competing risk model indicated better prognosis for jejunum versus duodenum in ADC (HR = 0.80, p = .048) and similar risks between ileum and duodenum tumors (HR = 0.99, p = .94), while location did not affect prognosis in GIST and NET (p > .05). Post-PSM, survival curves reconfirmed no significant difference between duodenum and ileum ADC (p > .05). Tumor location significantly influences prognosis in small intestine ADC, with duodenum tumors showing the worst outcomes. Location was not a significant prognostic factor in GIST and NET.</p>","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":5.7,"publicationDate":"2025-04-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143794275","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}